The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
New and emerging biotech companies face pressure to advance early-stage clinical trials while managing complex supply chain logistics. Many operate with limited funding tied to key clinical milestones, making any delay a critical risk. Disruptions in regulatory approvals, supply chain management, or site readiness can impact both trial success and financial stability. And unlike larger pharma companies with in-house infrastructure, many new and emerging biotechs rely on third-party partners for end-to-end support.
Our case study tells the story of one innovative biotech company that faced this reality while preparing for a global Phase II trial. They needed to achieve First Patient In (FPI) within just 14 weeks of signing their quote—an ambitious timeline made even more challenging by a holiday shutdown. Download this case study to learn how they partnered with Thermo Fisher Scientific to meet their clinical supply needs, including packaging, labeling, and regulatory translations, without compromising quality or compliance.
